Comparative Pharmacology
Head-to-head clinical analysis: GENCEPT 10 11 21 versus MICROGESTIN 1 5 30.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENCEPT 10 11 21 versus MICROGESTIN 1 5 30.
GENCEPT 10/11-21 vs MICROGESTIN 1.5/30
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GENCEPT 10/11-21 is a combination contraceptive vaginal ring containing ethinyl estradiol and etonogestrel. Ethinyl estradiol is an estrogen that suppresses gonadotropin release, inhibiting ovulation. Etonogestrel is a progestin that thickens cervical mucus, inhibiting sperm penetration, and alters the endometrium.
Combination oral contraceptive containing norethindrone acetate (progestin) and ethinyl estradiol (estrogen). Suppresses gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, preventing ovulation. Also increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (10 mg ethinyl estradiol and 11 mg gestodene on days 1-7, then placebo on days 8-21) orally once daily for 21 days, followed by 7 placebo days.
One tablet (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
None Documented
None Documented
Terminal elimination half-life is 24-30 hours; allows once-daily dosing; steady-state achieved in 5-7 days
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-19 hours. Steady-state reached within 5-7 days.
Renal (30-40% as unchanged drug and metabolites), biliary/fecal (50-60% as metabolites)
Renal: ~50-60% (primarily as glucuronide conjugates of ethinyl estradiol and norethindrone); Fecal: ~40-50% (via biliary elimination)
Category C
Category C
Oral Contraceptive
Oral Contraceptive